Literature DB >> 14693564

Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Klaus-Peter Hunfeld1, Thomas A Wichelhaus, Rebecca Rödel, Georg Acker, Volker Brade, Peter Kraiczy.   

Abstract

Two ketolides, three macrolides, and one azalide were tested in vitro against 17 isolates of the B. burgdorferi s.l. complex. As measured in micrograms per milliliter, activity was highest for cethromycin (MIC at which 90% of the tested isolates were inhibited [MIC(90)], 0.0019 micro g/ml) and telithromycin (MIC(90), 0.0078 micro g/ml). Electron-microscope analysis and time-kill studies also supported enhanced effectiveness of both ketolides.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14693564      PMCID： PMC310164          DOI： 10.1128/AAC.48.1.344-347.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances.

Authors:  K P Hunfeld; P Kraiczy; T A Wichelhaus; V Schäfer; V Brade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-01       Impact factor: 3.267

2.  In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.

Authors:  S Strigl; P M Roblin; T Reznik; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications.

Authors:  B A Odland; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Esterases in serum-containing growth media counteract chloramphenicol acetyltransferase activity in vitro.

Authors:  C D Sohaskey; A G Barbour
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors:  K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

6.  Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.

Authors:  V Preac Mursic; W Marget; U Busch; D Pleterski Rigler; S Hagl
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

7.  Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Authors:  F Strle; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

8.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

9.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values.

Authors:  J Boerner; K Failing; M M Wittenbrink
Journal:  Zentralbl Bakteriol       Date:  1995-11

10.  Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial.

Authors:  B J Luft; R J Dattwyler; R C Johnson; S W Luger; E M Bosler; D W Rahn; E J Masters; E Grunwaldt; S D Gadgil
Journal:  Ann Intern Med       Date:  1996-05-01       Impact factor: 25.391
View more
  4 in total

1.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

3.  In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.

Authors:  Kristina Morgenstern; Georg Baljer; Douglas E Norris; Peter Kraiczy; Christa Hanssen-Hübner; Klaus-Peter Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model.

Authors:  Jens Knauer; Inke Krupka; Christiane Fueldner; Joerg Lehmann; Reinhard K Straubinger
Journal:  J Antimicrob Chemother       Date:  2011-09-15       Impact factor: 5.790
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.